Healthy Clinical Trial
Official title:
Stearoyl-CoA Desaturase and Energy Metabolism in Humans
The aim of this study is to examine if changing stearoyl-coenzyme A desaturase-1 (SCD1) activity through dietary interventions can increase energy metabolism in humans.
In rodents as well as humans, high stearoyl-coenzyme A desaturase-1 (SCD1) activity is
considered to be involved in development of obesity. In animal models, polyunsaturated fatty
acids (PUFA) inhibit Scd1 gene expression and at the population level, dietary PUFA and
plasma PUFA show strong inverse associations with plasma SCD indices. Emerging evidence also
suggests a role for the sulphur amino acid cysteine in regulating SCD1 activity and obesity.
The overall aim of the project is to examine if interventions that lowers SCD1 activity lead
to increased energy metabolism. In this project, the investigators will conduct dietary
intervention trials to evaluate the effects of short-term consumption of a diet rich in
polyunsaturated fatty acids (PUFA) and low in cysteine and its precursor methionine
(PUFA‒Cys/Met) vs. a diet rich in saturated fatty acids (SFA) and cysteine/methionine
(SFA+Cys/Met) on SCD1 activity, lipids, amino acids, glucose and other biomarkers related to
energy metabolism, in healthy normal-weight subjects. Healthy volunteers will be randomized
to the PUFA‒Cys/Met or SFA+Cys/Met diets receiving supplements/meals in a single dose or for
7 days.
This study is a pilot study, with main focus on feasibility, tolerance and side effects. If
the pilot shows positive results in terms of side effects, safety and tolerance, the
investigators will follow-up by including obese subjects in a longer dietary intervention.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |